Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-20T09:20:38.289Z Has data issue: false hasContentIssue false

Basic science: (May 2008)

Published online by Cambridge University Press:  01 August 2008

R Sutherland
Affiliation:
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Journals Watch
Copyright
Copyright © Cambridge University Press 2008

References

1.Al-Azawi, D, Mc Ilroy, M, Kelly, G, Redmond, AM, Bane, FT, Cocchiglia, S, Hill, ADK, Young, LS. Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene 2008; 27: 30213031.CrossRefGoogle ScholarPubMed
2.Barabutis, N, Schally, AV. Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines. Br J Cancer 2008; 98: 17901796.CrossRefGoogle ScholarPubMed
3.Boulay, A, Breuleux, M, Stephan, C, Fux, C, Brisken, C, Fiche, M, Wartmann, M, Stumm, M, Lane, HA, Hynes, NE. The Ret receptor tyrosine kinase pathway functionally interacts with the ER α pathway in breast cancer. Cancer Res 2008; 68: 37433751.CrossRefGoogle ScholarPubMed
4.Elsheikh, S, Green, AR, Aleskandarany, MA, Grainge, M, Paish, CE, Lambros, MBK, Reis, JS, Ellis, IO. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome. Breast Cancer Res Treat 2008; 109: 325335.CrossRefGoogle ScholarPubMed
5.Euhus, DM, Bu, DW, Milchgrub, S, Xie, XJ, Bian, A, Leitch, AM, Lewis, CM. DNA methylation in benign breast epithelium in relation to age and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2008; 17: 10511059.CrossRefGoogle ScholarPubMed
6.Farrugia, DJ, Agarwal, MK, Pankratz, VS, Deffenbaugh, AM, Pruss, D, Frye, C, Wadum, L, Johnson, K, Mentlick, J, Tavtigian, SV, Goldgar, DE, Couch, FJ. Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res 2008; 68: 35233531.CrossRefGoogle ScholarPubMed
7.Fereshteh, MP, Tilli, MT, Kim, SE, Xu, JM, O’Malley, BW, Wellstein, A, Furth, PA, Riegel, AT. The nuclear receptor coactivator amplified in breast cancer-1 is required for neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice. Cancer Res 2008; 68: 36973706.CrossRefGoogle ScholarPubMed
8.Finak, G, Bertos, N, Pepin, F, Sadekova, S, Souleimanova, M, Zhao, H, Chen, HY, Omeroglu, G, Meterissian, S, Omeroglu, A, Hallett, M, Park, M. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518527.CrossRefGoogle ScholarPubMed
9.Frech, MS, Torre, KM, Robinson, GW, Furth, PA. Loss of cyclin D1 in concert with deregulated estrogen receptor α expression induces DNA damage response activation and interrupts mammary gland morphogenesis. Oncogene 2008; 27: 31863193.CrossRefGoogle ScholarPubMed
10.Golipour, A, Myers, D, Seagroves, T, Murphy, D, Evan, GI, Donoghue, DJ, Moorehead, RA, Porter, LA. The Spy1/RINGO family represents a novel mechanism regulating mammary growth and tumorigenesis. Cancer Res 2008; 68: 35913600.CrossRefGoogle ScholarPubMed
11.Hodges-Gallagher, L, Valentine, CD, El Bader, S, Kushner, PJ. Estrogen receptor β increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat 2008; 109: 241250.CrossRefGoogle ScholarPubMed
12.Hollingshead, BD, Beischlag, TV, DiNatale, BC, Ramadoss, P, Perdew, GH. Inflammatory signaling and aryl hydrocarbon receptor mediate synergistic induction of interleukin 6 in MCF-7 cells. Cancer Res 2008; 68: 36093617.CrossRefGoogle ScholarPubMed
13.Howarth, KD, Blood, KA, Ng, BL, Beavis, JC, Chua, Y, Cooke, SL, Raby, S, Ichimura, K, Collins, VP, Carter, NP, Edwards, PAW. Array painting reveals a high frequency of balanced translocations in breast cancer cell lines that break in cancer-relevant genes. Oncogene 2008; 27: 33453359.CrossRefGoogle ScholarPubMed
14.Hu, M, Yao, J, Carroll, DK, Weremowicz, S, Chen, H, Carrasco, D, Richardson, A, Violette, S, Nikolskaya, T, Nikolsky, Y, Bauerlein, EL, Hahn, WC, Gelman, RS, Allred, C, Bissell, MJ, Schnitt, S, Polyak, K. Regulation of in situ to invasive breast carcinoma transition. Cancer Cell 2008; 13: 394406.CrossRefGoogle ScholarPubMed
15.Jiao, W, Lin, HM, Datta, J, Braunschweig, T, Chung, JY, Hewitt, SM, Rane, SG. Aberrant nucleocytoplasmic localization of the retinoblastoma tumor suppressor protein in human cancer correlates with moderate/poor tumor differentiation. Oncogene 2008; 27: 31563164.CrossRefGoogle ScholarPubMed
16.Kaklamani, VG, Sadim, M, Hsi, A, Offit, K, Oddoux, C, Ostrer, H, Ahsan, H, Pasche, B, Mantzoros, C. Variants of the adiponectin and adiponectin receptor 1 genes and breast cancer risk. Cancer Res 2008; 68: 31783184.CrossRefGoogle ScholarPubMed
17.Kumar, AS, Benz, CC, Shim, V, Minami, CA, Moore, DH, Esserman, LJ. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev 2008; 17: 10281033.CrossRefGoogle ScholarPubMed
18.Li, XX, Lewis, MT, Huang, J, Gutierrez, C, Osborne, CK, Wu, MF, Hilsenbeck, SG, Pavlick, A, Zhang, XM, Chamness, GC, Wong, H, Rosen, J, Chang, JC. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672679.CrossRefGoogle ScholarPubMed
19.Ma, XJ, Salunga, R, Dahiya, S, Wang, W, Carney, E, Durbecq, V, Harris, A, Goss, P, Sotiriou, C, Erlander, M, Sgroi, D. A five-gene molecular grade index and HOXB13: IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 2008; 14: 26012608.CrossRefGoogle ScholarPubMed
20.Mao, C, Patterson, NM, Cherian, MT, Aninye, IO, Zhang, C, Montoya, JB, Cheng, J, Putt, KS, Hergenrother, PJ, Wilson, EM, Nardulli, AM, Nordeen, SK, Shapiro, DJ. A new small molecule inhibitor of estrogen receptor α binding to estrogen response elements blocks estrogen-dependent growth of cancer cells. J Biol Chem 2008; 283: 1281912830.CrossRefGoogle ScholarPubMed
21.Melchor, L, Honrado, E, Garcia, MJ, Alvarez, S, Palacios, J, Osorio, A, Nathanson, KL, Benitez, J. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene 2008; 27: 31653175.CrossRefGoogle ScholarPubMed
22.Mueller, KL, Hunter, LA, Ethier, SP, Boerner, JL. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 2008; 68: 33143322.CrossRefGoogle ScholarPubMed
23.Northey, JJ, Chmielecki, J, Ngan, E, Russo, C, Annis, MG, Muller, WJ, Siegel, PM. Signaling through ShcA is required for transforming growth factor β- and Neu/ErbB-2-induced breast cancer cell motility and invasion. Mol Cell Biol 2008; 28: 31623176.CrossRefGoogle ScholarPubMed
24.Qiu, W, Hu, M, Sridhar, A, Opeskin, K, Fox, S, Shipitsin, M, Trivett, M, Thompson, ER, Ramakrishna, M, Gorringe, KL, Polyak, K, Haviv, I, Campbell, IG. No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. Nat Genet 2008; 40: 650655.CrossRefGoogle ScholarPubMed
25.Schug, TT, Berry, DC, Toshkov, IA, Cheng, L, Nikitin, AY, Noy, N. Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARβ/δ to RAR. Proc Natl Acad Sci USA 2008; 105: 75467551.CrossRefGoogle ScholarPubMed
26.Shafee, N, Smith, CR, Wei, SZ, Kim, Y, Mills, GB, Hortobagyi, GN, Stanbridge, EJ, Lee, E. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 2008; 68: 32433250.CrossRefGoogle ScholarPubMed
27.Shakya, R, Szabolcs, M, McCarthy, E, Ospina, E, Basso, K, Nandula, S, Murty, V, Baer, R, Ludwig, T. The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression. Proc Natl Acad Sci USA 2008; 105: 70407045.CrossRefGoogle ScholarPubMed
28.Smid, M, Wang, YX, Zhang, Y, Sieuwerts, AM, Yu, J, Klijn, JGM, Foekens, JA, Martens, JWM. Subtypes of breast cancer show preferential site of relapse. Cancer Res 2008; 68: 31083114.CrossRefGoogle Scholar
29.Van den Eynden, GG, Smid, M, Van Laere, SJ, Colpaert, CG, Van der Auwera, I, Bich, TX, van Dam, P, den Bakker, MA, Dirix, LY, Van Marck, EA, Vermeulen, PB, Foekens, JA. Gene expression profiles associated with the presence of a fibrotic focus and the growth pattern in lymph node-negative breast cancer. Clin Cancer Res 2008; 14: 29442952.CrossRefGoogle ScholarPubMed
30.Vultur, A, Buettner, R, Kowolik, C, Liang, W, Smith, D, Boschelli, F, Jove, R. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells. Mol Cancer Ther 2008; 7: 11851194.CrossRefGoogle ScholarPubMed
31.Wu, KM, Katiyar, S, Li, AP, Liu, MR, Ju, XM, Popov, VM, Jiao, XM, Lisanti, MP, Casola, A, Pestell, RG. Dachshund inhibits oncogene-induced breast cancer cellular migration and invasion through suppression of interleukin-8. Proc Natl Acad Sci USA 2008; 105: 69246929.CrossRefGoogle ScholarPubMed
32.Yang, XWH, Richardson, AL, Torres-Arzayus, MI, Zhou, PC, Sharma, C, Kazarov, AR, Andzelm, MM, Strominger, JL, Brown, M, Hemler, ME. CD151 accelerates breast cancer by regulating α(6) integrin function, signaling, and molecular organization. Cancer Res 2008; 68: 32043213.CrossRefGoogle ScholarPubMed